Merck KGaA Tightens Focus With Allergopharma Sale
Allergens Business Acquired By Dermapharm For Undisclosed Sum
Germany’s family-controlled big pharma, Merck KGaA, is divesting its allergens business, Allergopharma to the fast-growing Munich healthcare company, Dermapharm Holding.
You may also be interested in...
The German company is exposed to events in China across its three divisions - healthcare, life sciences and performance materials - but says that COVID-19 should only affect 2020 sales by 1%, unless a global recession happens.
P&G names Merck KGAA consumer chief Uta Kemmerich-Keil to lead international division of personal health business as it closes on $4.2bn acquisition of German firm's consumer business. Deal closes a month after P&G announced biggest changes to organizational structure in 20 years, including combining personal care and health care into personal health and forming six global units, each headed by a CEO.
Public Company Edition: With returns for newly public biopharma companies rising, seven more jumped in line to go public in the US between the beginning of February and early March, while two drug developers launched IPOs in the EU. Meanwhile, already public companies keep raising gobs of cash.